Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorHernando, J.
dc.contributor.authorManzano, J. L.
dc.contributor.authorTeule, A.
dc.contributor.authorLopez, C.
dc.contributor.authorGarcia-Carbonero, R.
dc.contributor.authorBenavent Vinuales, M.
dc.contributor.authorCustodio, A.
dc.contributor.authorCubillo, A.
dc.contributor.authorAlonso, V.
dc.contributor.authorAlonso-Gordoa, T.
dc.contributor.authorCarmona-Bayonas, A.
dc.contributor.authorCrespo, G.
dc.contributor.authorBlanco, M.
dc.contributor.authorJimenez-Fonseca, P.
dc.contributor.authorViudez, A.
dc.contributor.authorLa Casta, A.
dc.contributor.authorSevilla, I.
dc.contributor.authorLlanos, M.
dc.contributor.authorSegura, A.
dc.contributor.authorCapdevila, J.
dc.contributor.authoraffiliation[Hernando, J.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Capdevila, J.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Manzano, J. L.] Inst Catala Oncol ICO Badalona, Hosp Germans Trias i Pujol, Dept Med Oncol, Badalona, Spain
dc.contributor.authoraffiliation[Teule, A.] Inst Catala Oncol ICO IDIBELL, Med Oncol Dept, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Lopez, C.] Hosp Univ Marques Valdecilla, IDIVAL, Med Oncol Dept, Santander, Spain
dc.contributor.authoraffiliation[Garcia-Carbonero, R.] Hosp Univ 12 Octubre, Imas12, UCM CNIO, Med Oncol Dept, Madrid, Spain
dc.contributor.authoraffiliation[Benavent Vinuales, M.] Univ Hosp Virgen Rocio, Inst Biomed Sevilla IBIS, Med Oncol Dept, Seville, Spain
dc.contributor.authoraffiliation[Custodio, A.] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Cubillo, A.] Hosp Univ HM Sanchinarro, Med Oncol Dept, Madrid, Spain
dc.contributor.authoraffiliation[Alonso, V.] Inst Invest Sanitaria Aragon IISA, Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain
dc.contributor.authoraffiliation[Alonso-Gordoa, T.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Carmona-Bayonas, A.] Hosp Univ Morales Meseguer, UMU, IMIB, Hematol & Med Oncol Dept, Murcia, Spain
dc.contributor.authoraffiliation[Crespo, G.] Complejo Asistencial Univ Burgos, Med Oncol Dept, Burgos, Spain
dc.contributor.authoraffiliation[Blanco, M.] Hosp Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain
dc.contributor.authoraffiliation[Jimenez-Fonseca, P.] Hosp Univ Cent Asturias, ISPA, Med Oncol Dept, Oviedo, Spain
dc.contributor.authoraffiliation[Viudez, A.] Complejo Hosp Navarra, Medica Oncol Dept, Pamplona, Spain
dc.contributor.authoraffiliation[La Casta, A.] Hosp Univ Donostia, Dept Med Oncol, San Sebastian, Spain
dc.contributor.authoraffiliation[Sevilla, I.] Hosp Univ Reg & Virgen Victoria Malaga, Inst Invest Biomed Malaga IBIMA, Invest Clin & Traslac Canc, Med Oncol Dept, Malaga, Spain
dc.contributor.authoraffiliation[Llanos, M.] Hosp Univ Canarias, Med Oncol Dept, San Cristobal la Laguna, Spain
dc.contributor.authoraffiliation[Segura, A.] Hosp Univ Fe, Med Oncol Dept, Valencia, Spain
dc.contributor.funderAstraZeneca
dc.date.accessioned2025-01-07T15:18:05Z
dc.date.available2025-01-07T15:18:05Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.181
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.181
dc.identifier.urihttps://hdl.handle.net/10668/27027
dc.identifier.wosID700527702117
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS909-S910
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleDurvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía